Abstract | BACKGROUND: PATIENTS AND METHODS: Twenty obese PCOS patients [BMI 33.7 ± 6 kg/m2 (mean ± SD)] were recruited. The lipid profile was assessed by measuring total cholesterol, LDL, HDL and triglycerides before and after 6 months treatment with the combined therapy. Secondary end points included changes in BMI, waist-hip ratio, percentage of body fat, HOMA-IR and blood pressure. RESULTS: The combined therapy myo- inositol and D- chiro-inositol improved LDL levels (3.50 ± 0.8 mmol/L versus, 3 ± 1.2 mmol/L p < 0.05), HDL (1.1 mmol/L ± 0.3 versus 1.6 mmol/L ± 0.4 p < 0.05) and triglycerides (2.3 ± 1.5 mmol/L versus 1.75 ± 1.9 mmol/L p < 0.05). Furthermore, significant improvements in HOMA-IR were also observed. CONCLUSIONS: The combined therapy myo- inositol plus D- chiro-inositol is able to improve the metabolic profile of PCOS women, therefore, reducing the cardiovascular risk.
|
Authors | M Minozzi, M Nordio, R Pajalich |
Journal | European review for medical and pharmacological sciences
(Eur Rev Med Pharmacol Sci)
Vol. 17
Issue 4
Pg. 537-40
(Feb 2013)
ISSN: 1128-3602 [Print] Italy |
PMID | 23467955
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Cardiovascular Diseases
(etiology, metabolism, prevention & control)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Humans
- Inositol
(administration & dosage, chemistry, therapeutic use)
- Lipid Metabolism
(drug effects)
- Lipids
(blood)
- Longitudinal Studies
- Obesity
(complications, drug therapy, metabolism)
- Polycystic Ovary Syndrome
(complications, drug therapy, metabolism)
- Risk Factors
- Stereoisomerism
- Treatment Outcome
|